Suchergebnisse - "Goldschmidt, Hartmut"

PubPharm (42)

1

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

enthalten in: Leukemia | 2021

von Salwender, H. | Elmaagacli, A. | Merz, M. | +21

2

KarMMa-RW : comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

enthalten in: Blood cancer journal | 2021

von Jagannath, S. | Lin, Y. | Goldschmidt, H. | +14

3

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma : matching-adjusted indirect comparison

enthalten in: Immunotherapy | 2021

von Moreau, P. | Hebraud, B. | Facon, T. | +23

4

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups

enthalten in: Clinical lymphoma, myeloma & leukemia | 2019

von Orlowski, R. | Moreau, P. | Niesvizky, R. | +7

5

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS) : comparison with multiple myeloma

enthalten in: Leukemia | 2019

von Thomsen, H. | Chattopadhyay, S. | Weinhold, N. | +15

6

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

enthalten in: Leukemia & lymphoma | 2019

von Kumar, S. | Durie, B. | Nahi, H. | +13

7

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR) : an interim overall survival analysis of an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2017

von Dimopoulos, M. | Goldschmidt, H. | Niesvizky, R. | +14

CommentIn: Lancet Oncol. 2017 Oct;18(10):1288-1290. - PMID 28843767

8

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

enthalten in: The Lancet. Oncology | 2016

von Dimopoulos, M. | Moreau, P. | Palumbo, A. | +129

CommentIn: Lancet Oncol. 2016 Jan;17(1):2-3. - PMID 26671819

9

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

enthalten in: BMC medical genomics | 2015

von Meißner, T. | Seckinger, A. | Hemminki, K. | +9

10

Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease

enthalten in: European journal of radiology | 2014

von Wolf, M. | Murray, F. | Kilk, K. | +7

1
2
3
4
5
Nächster »
[5]